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Abstract  
Introduction: Very few studies have been conducted to evaluate the prevalence of hyperuricemia and its impact on the prognosis amongst acute 
hemorrhagic stroke (AHS) patients. The objectives was to determine the prevalence of hyperuricemia in AHS patients and examined the 
association between hyperuricemia and stroke outcomes in the Douala General Hospital (DGH). Methods: This was a hospital based prospective 
cohort which included AHS patients with baseline SUA levels and 3 months post stroke follow-up data. SUA values were divided into quintiles. 
Associations between hyperuricemia and stroke outcomes were analyzed using multiple logistic regression and survival analysis (cox regression 
and Kaplan Meier). Results: A total of 221 AHS patients were reviewed with a mean age of 55.8±11.8 years. The prevalence of hyperuricemia 
among AHS patients was 34.4% with mean SUA level of 376.8±131.9 µmol/l. On multivariate analysis, hyperuricemia was not independently 
associated with early death [(OR = 1.072 (CI: 0.370-3.056; p = 0.897)] and poor functional outcome [(OR=2.487 (CI: 0.771-8.699; p = 0.154)] 
after hemorrhagic stroke. No significant increase in stroke deaths was observed across higher SUA quintiles amongst hemorrhagic stroke patients 
(p = 0.326). No statistically significant correlation was observed between SUA level and NIHSS (r = 0.063, p = 0.353) and between SUA level and 
mRS (r = 0.030, p = 0.662) in hemorrhagic stroke. Conclusion: About one third of patients present with hyperuricemia in the acute phase of 
hemorrhagic stroke. Hyperuricemia can act as risk factor for stroke because of its relationship with CVRFs but hyperuricemia has no impact on the 
severity and short-term outcome amongst black African hemorrhagic stroke patients. 
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Introduction 
 
Stroke is the second leading cause of death and the leading cause 
of adult disability worldwide [1, 2]. Stroke ranks 6th out of the top 
ten causes of death and accounts for one of the top frequent 
neurological disease consulting at the neurology units [3]. The 
burden of stroke seems to be shifting to the developing world and 
currently two-thirds of stroke mortality cases occur in sub-Saharan 
Africa [4, 5]. In Africa, stroke case fatality ranges from 31.9% to as 
high as 69.7% when due to hemorrhagic stroke [6-8]. Uric acid is a 
powerful anti-oxidant that exerts neuroprotective effects by acting 
as a free radical scavenger in plasma [9-11]. It has been reported 
that increased levels of uric acid are associated with established 
cardiovascular risk factor such as elevated serum triglyceride and 
cholesterol concentration, hypertension, obesity, insulin resistance 
and metabolic syndrome [9, 12]. The role of SUA in acute stroke is 
poorly understood since some studies demonstrate that SUA is 
associated with adverse outcomes and mortality [13-18] while other 
studies are suggesting that SUA may be beneficial and protect 
against poor outcomes [19, 20]. Despite these controversies as to 
whether there is a relation between SUA levels and outcome after 
acute stroke, the role of SUA in the acute phase of hemorrhagic 
stroke only has received scant attention in world literature. 
Therefore, in this study we estimated the prevalence of 
hyperuricemia in hemorrhagic stroke and determined its relationship 





Patients and study design: We carried out a hospital based 
prospective cohort study in a tertiary care hospital in Douala, 
Cameroon. We included consenting patients admitted for 
hemorrhagic stroke in the neurology unit of the department of 
internal medicine and the intensive care unit of the Douala General 
Hospital (DGH) from January 2010 to January 2016. This study was 
approved by the Institutional Ethics Committee of Research on 
Human Health of the University of Douala and the study hospital-
DGH. Patients who were admitted for confirmed hemorrhagic stroke 
within 7 days of onset of symptoms were included in our study. 
Patients with incomplete files, acute ischemic stroke and cerebral 
venous thrombosis were excluded. 
  
Data collection and patient management: Demographic data, 
including age, sex and relevant medical history such as hypertension 
(HTN), diabetes mellitus (DM), smoking history, alcohol abuse, use 
of diuretics, history of diseases like chronic kidney disease (CKD), 
gout and other cardiovascular events such as atrial fibrillation, 
congestive heart failure (CHF), coronary artery disease (CAD) and 
ischemic heart disease (IHD) were recorded. Baseline vital and 
anthropometric parameters such as blood pressure, pulse, 
respiratory rate, oxygen saturation weight, height and an abdominal 
circumference values were recorded using standard operating 
procedures. The following definitions and standard operating 
techniques were used to identify risk factors for stroke in each 
subject: hypertension was defined as patient with medical history of 
hypertension, treated or not and patient with persistent high blood 
pressure > 140/90 mmHg after stroke. Diabetes Mellitus was 
defined as patient with medical history of diabetes, treated or not, 
random serum glucose ≥ 11.1 mmol/l or venous fasting glucose test 
≥ 6.99 mmol/l. Dyslipidemia was defined as patient with medical 
history of dyslipidemia or Total cholesterol (TC) > 5.2 mmol/l or 
Low-density lipoprotein (LDLc) > 2.59 mmol/l or High-density 
lipoprotein (HDLc) < 1.0 mmol/l in males or < 1.3 mmol/l in 
females, triglycerides (TG) > 1.7 mmol/l. The presence of the 
metabolic syndrome was determined using the new definition [21]. 
Alcohol abuse defined as daily alcohol intake > 40 g/l. Obesity was 
defined as patient with a body mass index (BMI) > 30 and when it's 
impossible to have the BMI, we use the abdominal circumference: 
>102 cm in male and >88 cm in female. Smoking was defined as 
patient with history of smoking (current smokers and ex-smokers) 
quantified in pack years. Sleep apnea syndrome (SAS) was defined 
as patient with a medical history of SAS diagnosed before or after 
stroke onset using pulse oximetry in patients with suggestive 
symptoms such as snoring, witnessed apnea, daytime sleepiness 
and the presence of comorbidities hypertension, heart failure and 
obesity. Patients with severe conditions like a Glasgow Coma Scale 
< 8/15 or septic shock were directly admitted in the ICU while other 
cases were hospitalized in the NU. 
  
Blood sample was collected from all patients during the first 24 
hours of admission to check SUA levels, fasting blood sugar, 
complete metabolic panel (urea, creatinine, uric acid, electrolytes 
etc) and lipid profile using the Cobas 311 autoanalyzers. A full blood 
count with platelet counts, prothrombin time, cephaline-kaolin time, 
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and 
HIV serology were done. Other tests were prescribed if required by 
the patient's conditions: chest X-ray, urine culture, blood culture, 
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and thick blood film to check for plasmodium falciparum. 
Neurological assessment was done by a neurologist or intensive 
care specialist. Interpretation of CT scans was done by both 
radiologist and neurologist and its findings were recorded. The type 
of stroke was also recorded. Electrocardiography was systematically 
done for hypertensive patients with hemorrhagic stroke. On 
admission and at 3 months post stroke, the Glasgow coma scale 
(GCS) and the National Institute of Health Stroke Scale (NIHSS) 
were used to determine the stroke severity while the functional 
outcome was evaluated by the modified Rankin score (mRS). Stroke 
death and stroke recurrence during admission and within 3 months 
post stroke was also recorded. In case of death, the staff had to be 
precise about the cause of death. Poor (bad) functional outcome 
was considered in patients with mRS > 2 within the first 3 months 
post stoke discharge while good functional outcome was considered 
in patients who are alive within the first 3 months post stroke and 
with mRS ≤ 2. Follow up was done daily for clinical evaluation and 
complications were noted. Oxygen was administrated if ambient 
oxygen saturation was less than 94%. Paracetamol was used 1g 
every six hours if temperatures higher than 37.50C were noted. 
Prevention of deep venous thrombosis and stress ulcers was done 
using prophylactic dose of enoxaparin (40mg) and omeprazole 
(20mg), respectively. An insulin protocol was set up when capillary 
glycaemia was above 7.8 mmol/l. Concerning the blood pressure, 
nicardipine was given intravenously with electric syringe in case of 
high blood pressure with a target of 140 to 160mmHg for systolic 
blood pressure in hemorrhagic stroke. Antibiotics and artemether 
were used for bacterial infection and malaria, respectively. 
  
Statistical analysis: Statistical analysis was done using the 
Statistical Package for Social Sciences (SPSS) Standard version, 
Release 20.0 (IBM Inc. 2012). Mean and standard deviation (SD) of 
all continuous data are reported. SUA was a scale variable but was 
categorized into two groups, those having normal and high SUA 
levels (hyperuricemia) as follows; normal SUA range was SUA ≤ 
356.9 µmol/l in females and SUA ≤ 416.4 µmol/l in males while high 
SUA range was SUA > 356.9 µmol/l in females and SUA > 416.4 
µmol/l in males. SUA was also divided into quintiles (mean SUA level 
per quintile range) as follows: Q1 ≤ 291.5 µmol/l (249.4 µmol/l), Q2 
= 297.4-356.9 µmol/l (329.6 µmol/l), Q3 = 362.8-416.4 µmol/l 
(391.6 µmol/l), Q4 = 422.3-499.7 µmol/l (457.5 µmol/l) and Q5 ≥ 
505.6 µmol/l (627.3 µmol/l). Hyperglycemia was defined as glucose 
levels > 7.8 mmol/l), high TC considered as TC levels > 5.2 mmol/l, 
high LDLc considered as LDLc levels > 2.59 mmol/l or decreased 
HDLc considered as HDLc levels < 1.0 mmol/l in males or < 1.3 
mmol/l in females and high TG considered as TG levels > 1.7 
mmol/l. Independent Samples t-test was used to assess differences 
in continuous variables since the normality assumption was not 
violated following Kolmogorov-Smirnov and Shapiro-Wilk test for 
normality. Cramer's V, Chi Square test and Fisher's Exact Test were 
used for categorical variables. Univariate analysis was first 
performed with demographic characteristics and the risk factors of 
stroke by cross-tabulations with X2 or Fisher's exact tests for the 
unadjusted odds ratios (ORs) and then multiple logistic regression 
was done to adjust the confounding effects of the dependent 
predictors of death during admission. All predictor variables with p 
values < 0.2 that were gotten from the univariate analysis were 
included in our multivariate analysis. Survival analysis was 
performed using Kaplan Meier and Cox regression analysis. Level of 





Basic characteristics of the study population: Table 1 shows 
the basic characteristics of the study population: A total of 221 
patients with hemorrhagic stroke were included amongst which 134 
were males (60.6%). The mean age was 55.8±11.8 years with most 
patients aged 46-60 years (49.8%). Table 1 lists the demographics, 
the vascular risk factors and clinical parameters of the study 
population. The most prevalent vascular risk factors were 
hypertension and hyperlipidemia, which were present in 96.8% and 
66.5% of the patients respectively. About 14.0% of the study 
population had experienced another stroke in the past. The 
prevalence of hyperuricemia in hemorrhagic stroke patients was 
34.4% (76/221). Of the 221 participants, the prevalence of CKD 
was seen in 2.7%. The mean SUA level was 376.5±131.8 µmol/l, 
while the mean SUA levels in the male patients (392.8±121.1 
µmol/l) was significantly higher than amongst the female patients 
(352.1±144.1 µmol/l) with p=0.024. The proportion of females with 
high SUA level [33(37.9%)] was lower than the proportion of 
females with normal SUA level [54(62.1%)]. Among the males, the 
trend was the same, with a lower proportion of 43 (32.1%) males 
having high SUA levels as compared to 91 (67.9%) with normal SUA 
levels. 
  
Outcome in the acute phase and 90 days post stroke: The 
outcome of patients within the 90 days post stroke has been 
assessed in Figure 1. In this series, 74 out of 221 patients (33.5%) 
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died during admission and 147 patients (66.5%) discharged home 
alive were eligible for follow up amongst which 12.2% (18/147) died 
within three months and 17.0% (25/147) were lost to follow up. 
Among stroke survivors (n=104), 60.6% and 39.4% had good and 
bad functional outcomes. Overall, the 3 months post stroke 
mortality was 46.9% (92/196). The mean SUA concentration ± SD 
(standard deviation) of stroke survivors of 354.9 ± 91.7 µmol/l was 
significantly lower than that of those who died 388.8 ± 118.0 
µmol/l, p-value=0.025. The mean ± SD duration of hospital stay 
and of follow up was 9.7 ± 7.0 days and 49.9 ± 40.7 days 
respectively. 
  
Correlation between SUA and clinical data on 
admission: Table 2 shows the correlation between SUA and clinical 
data on admission; there was a weak negative significant correlation 
between age and SUA concentration (r = -0.158*, p=0.019, n=221) 
and there was also a weak negative significant correlation between 
Glasgow coma score and SUA concentration (r=-0.137*p = 0.042, n 
= 221). SUA concentrations had strong positive significant 
correlations with systolic blood pressure (r = 0.218**p = 0.001, n = 
221), diastolic blood pressure (r = 0.236**, p =< 0.001, n = 221), 
creatinine (r = 0.532**, p =< 0.001, n = 221), urea (r = 0.234**, p 
=< 0.001, n = 221), triglycerides (r = 0.188**, p = 0.009, n = 191) 
and low density lipoprotein cholesterol (r = 0.165*, p = 0.022, n = 
191). There was a positive but insignificant correlation between 
glycemia levels and SUA concentration (r = 0.114, p = 0.091, n = 
221). There was no significant correlation between length of 
hospital stay and SUA concentration (r = 0.093, p = 0.167, n = 
221). 
  
Comparison of SUA levels with CVRFs amongst hemorrhagic 
stroke patients: Table 3 shows the comparison of SUA levels with 
CVRFs amongst hemorrhagic stroke patients: Significant 
associations were observed between SUA levels and the following 
CVRFs; alcohol abuse [p = 0.049], dyslipidemia [p = 0.011], obesity 
[p = 0.026], metabolic syndrome [p = 0.026] and chronic kidney 
disease [p = 0.019]. 
  
Predictive value of SUA on mortality amongst hemorrhagic 
stroke patients: On univariate analysis, the following were factors 
significantly associated with death in acute hemorrhagic stroke: lack 
of insurance, history of smoking, alcohol abuse, dyslipidemia, 
metabolic syndrome, hyperglycemia, low HDLc, increased 
triglycerides, high total cholesterol, GCS less than 9, NIHSS > 14, 
mRS > 2 and presence of in-hospital complications (p < 0.05). On 
univariate analysis, there was no significant association between 
high SUA levels and death among acute hemorrhagic stroke patients 
[(p = 0.172, OR = 1.515, 95% CI: 0.833-2.753)]. On multivariate 
analysis, no such independent association was seen between 
hyperuricemia and mortality amongst hemorrhagic stroke patients 
[(OR = 1.072 (CI: 0.370-3.056; p = 0.897)]. After multivariate 
analysis, only GCS less than 9, NIHSS greater than 14 and 
hyperglycemia remained as significant independent predictors of 
death within 3 months amongst hemorrhagic stroke patients (p < 
0.05). A history of HTN was a protective factor against death 
amongst hemorrhagic stroke patients. Furthermore, no independent 
association between increasing SUA concentration and survival was 
noted with the Kaplan Meier curve with adjusted HR (95% CI) of 
1.374 (0.902-2.094); P = 0.139, as shown in Figure 2. As shown 
in Figure 3, the proportion of the death on admission amongst 
hemorrhagic stroke patients did not significantly increase with high 
levels of SUA (P = 0.326). The proportion of deaths in the 2nd SUA 
quintile range (SUA = 297.4-356.9 µmol/l) and 4th quintile range 
(SUA = 422.3-499.7 µmol/l) had the highest proportion of deaths, 
19 (25.7%) and 17 (23.0%) respectively while the 5thSUA quintile 
range had the lowest proportion of deaths on admission, 10 
(13.5%) (Table 4). 
  
Predictive value of SUA on functional outcome in 
hemorrhagic stroke: On univariate analysis, the following were 
factors significantly associated with poor functional outcome in 
hemorrhagic stroke: history of heart disease, GCS less than 9, 
NIHSS >14 and mRS > 2 (p < 0.05). On univariate analysis, there 
was no significant association between high SUA levels and with 
poor functional outcome amongst acute hemorrhagic stroke patients 
[(p = 0.187, OR=1.846, 95% CI: 0.781-4.364)]. On multivariate 
analysis, no such independent association was seen between 
hyperuricemia and with poor functional outcome amongst 
hemorrhagic stroke patients [(OR = 2.487 (CI: 0.771-8.699; p = 
0.154)]. After multivariate analysis, only mRS > 2 remained as 
significant independent predictors of poor functional outcome within 






According to our findings, we observed that the prevalence of 
hyperuricemia amongst hemorrhagic stroke patients was 34.4% 
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(76/221). Secondly, SUA concentrations had positive significant 
correlations with SBP, DBP, creatinine, urea, triglycerides and LDL 
cholesterol while significant associations were observed between 
high SUA levels and the following CVRFs; alcohol abuse, 
dyslipidemia, obesity, metabolic syndrome and chronic kidney 
disease. Thirdly, we equally observed that hyperuricemia was not an 
independent predictor of stroke death and poor functional outcome 
amongst hemorrhagic stroke patients. Most epidemiological studies 
have reported a significant association between elevated SUA and 
increased cerebrovascular disease [22]. However, many studies 
have evaluated the prognostic significance of SUA in acute ischemic 
stroke and acute stroke (both ischemic and hemorrhagic stroke) but 
very few studies have reported on the impact of SUA on the 
prognosis of hemorrhagic stroke [15, 17, 23, 24]. In Ghana, Sarfo et 
al.. in an observational prospective study reported the prevalence of 
hyperuricemia of 46.3% amongst acute stroke patients and similar 
to our findings, early mortality was not significantly associated with 
hyperuricemia in hemorrhagic stroke [14]. Similarly in Iran, 
Mehrpour et al., reported the prevalence of 47.3% amongst 55 
patients (46 ischemic and 9 hemorrhagic stroke patients) [25]. 
Conversely, the prevalence of hyperuricemia in patients with 
ischemic stroke is even higher as demonstrated by Koppula et 
al. [13]. With regards to the relationship between SUA and CVRFs, 
our findings are in accordance to the Iranian study where a 
significant negative correlation between SUA with the age of 
patients and hyperuricemia was associated increased amounts of TG 
and LDLc [25]. Furthermore our findings are also similar to those 
reported in a population-based cross-sectional study conducted by 
Qin et al., in Shanghai, where SUA levels were positively associated 
with BMI, waist circumference, triglycerides and negatively 
associated with HDL-cholesterol [26]. Contrarily, no significant 
association was seen between these modifiable CVRFs and high SUA 
in stroke patients in the Ghanaian study [14]. This difference can be 
accounted for by differences in the methodology and the sample 
size in the Ghanaian study was small (147). Therefore, it is possible 
to conclude that this high prevalence of hyperuricemia may simply 
reflect its association or correlation with CVRFs present amongst 
hemorrhagic stroke patients. 
  
In our study, we found no statistically significant correlation 
between SUA level and NIHSS and between SUA level and mRS in 
hemorrhagic stroke. We also noted a weak negative significant 
correlation between Glasgow coma score and SUA concentration. 
Similarly, Bandyopadhyay et al.. in India found a statistically 
insignificant weak positive correlation between uric acid level and 
change of Mathew score in hemorrhagic stroke patients [16]. Unlike 
our study, Ryu et al., in Korea demonstrated that SUA is 
independently associated with the presence of cerebral microbleeds 
(CMBs) and the relation between uric acid and CMBs was robust in 
hypertensive patients [27]. Holme et al.. concluded that increasing 
SUA levels were associated with increased risk of both hemorrhagic 
and ischemic strokes [28]. Also, according to Bandyopadhyay et al., 
in New Delhi, amongst 96 acute stroke patients, high SUA level was 
insignificantly associated with poor neurological outcome in patients 
with hemorrhagic stroke [16]. In a Congolese cohort, 
hyperuricaemia was found to be predictor of stroke and all-cause 
mortality [29]. In 2009, Kim et al., showed that patients with 
hyperuricemia were found to be at a significantly higher risk for 
both stroke incidence and mortality than controls with normal levels 
of SUA and after adjusting for known risk factors of stroke, the 
significance between hyperuricemia and stroke remained [22]. 
Strasak et al., in a prospective long-term study of 83 683 Austrian 
men demonstrated that increased SUA and the highest quintile is 
independently related to mortality from CHF and stroke [30]. It is 
worth noting that even though no significant association was found 
between uric acid and poor outcomes in hemorrhagic stroke, high 
uric acid levels in the acute phase of stroke could have occurred as 
a result its association with CVRFs such increasing age, 
hypertension, alcohol abuse, dyslipidemia, obesity and metabolic 
syndrome. Regardless of these findings, it is therefore possible to 
imply that hyperuricemia is a possible risk factor for stroke and 
primary prevention of stroke will be crucial in the reduction of 
mortality and morbidity related to hemorrhagic stroke amongst 
Cameroonians. The strength of this study was the fact that we 
prospectively explored different aspects of stroke outcomes in 
relation to uric acid amongst a cohort of patients with ICH but as a 
limitation, we were not able to explore certain variables that could 
have been more appropriate such the glycated hemoglobin (HbA1c). 
We used blood glucose levels in the study instead of the HbA1c 
hence overestimating the proportion of patients with diabetes 
mellitus as stress hyperglycemia could occur in acute conditions 
such as stroke. Despite these limitations, we have been able to 





Our findings suggest that one third of patients present with 
hyperuricemia in the acute phase of hemorrhagic stroke. 
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Hyperuricemia can act as a risk factor for stroke because of its 
relationship with CVRFs but it is not an independent predictor of the 
mortality and adverse outcome amongst black African hemorrhagic 
stroke patients. 
 
What is known about this topic 
 The role of serum uric acid (SUA) in the acute phase of 
stroke remains controversial: there are studies which 
demonstrate their negative role in stroke outcome while 
others shows protective role; 
 SUA is shown to influence the outcome of acute stroke in 
terms of mortality and functional outcome; 
 Little is known in the black African leaving in Africa. 
What this study adds 
 This study gives the prevalence of hyperuricemia among 
hemorrhagic stroke patients in a black African population; 
 SUA does not influence the outcome of hemorrhagic 
stroke in terms of mortality and functional outcome; 
 Even with increased level of SUA (quintile), there is no 
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Table 1: Basic characteristics of the study population 
Variables Values 
Male, n (%) 134 (60.6) 
Age, years (Mean±SD) 55.8±11.8 
Hypertension, n (%) 214 (96.8) 
Diabetes Mellitus, n (%) 53 (24.0) 
Smoking, n (%) 36 (16.3) 
Alcohol Intake, n (%) 85 (38.5) 
Dyslipidemia, n (%) 147 (66.5) 
Obesity, n (%) 48 (21.7) 
Metabolic Syndrome, n (%) 43 (19.5) 
Migraine, n (%) 14 (6.3) 
Sleep Apnea Syndrome, n (%) 19 (8.6) 
Use of Oral Contraceptives, n (%) 1 (0.5) 
Coronary Artery Disease, n (%) 7 (3.2) 
Atrial fibrillation, n (%) 7 (3.2) 
Heart disease, n (%) 12 (5.4) 
Valvulopathy, n (%) 5 (2.3) 
Past Stroke, n (%) 31 (14.0) 
Sedentary Lifestyle, n (%) 18 (8.1) 
Family History of stroke, n (%) 8 (3.6) 
Hyperuricemia, n (%) 76 (34.4) 
Chronic kidney disease, n (%) 6 (2.7) 
HIV Seropositive, n (%) 6 (2.7) 
Systolic Blood Pressure (Mean±SD), mmHg 178.9±34.4 
Diastolic Blood Pressure (Mean±SD), mmHg 107.6±22.1 
Body Mass Index (Mean±SD), Kg/m2 30.3±5.6 
Glasgow Coma score (Mean±SD) 11.4±3.8 
NIHSS Score (Mean±SD) 16.5±10.1 
Modified Rankin Score (Mean±SD) 3.7±1.3 
Serum Uric Acid (Mean±SD), µmol/l 376.5±131.8 
Serum Uric Acid in males (Mean±SD), µmol/l 392.8±121.1 
Serum Uric Acid in females (Mean±SD), µmol/l 352.1±144.1 
Creatinine (Mean±SD), µmol/l 160.9±38.4 
Urea (Mean±SD), mmol/l 2.4±0.7 
Glycemia (Mean±SD), mmol/l 7.9±4.0 
Glycated hemoglobin (Mean±SD), % 6.8±1.7 
Total Cholesterol (Mean±SD). mmol/l 5.1±0.7 
Triglycerides (Mean±SD). mmol/l 1.3±0.6 
HDL Cholesterol (Mean±SD). mmol/l 1.3±0.5 
LDL Cholesterol (Mean±SD). mmol/l 3.3±1.6 
NIHSS: National Institute of Health Stroke Scale, HDL: High density lipoprotein 
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Table 2: Correlation between SUA and clinical data on admission 
Variables R P value Total 
Age -0.158* 0.019 221 
Systolic blood pressure 0.218** 0.001 221 
Diastolic blood pressure 0.236** <0.001 221 
Body Mass Index 0.164 0.171 71 
NIHSS 0.063 0.353 221 
mRS 0.030 0.662 221 
Glasgow coma score -0.137* 0.042 221 
Creatinine 0.532** <0.001 221 
Urea 0.234** <0.001 221 
Glycemia 0.114 0.091 221 
Total cholesterol -0.095 0.191 191 
Triglycerides 0.188** 0.009 191 
High density lipoprotein 
cholesterol 
0.077 0.290 191 
Low density lipoprotein 
cholesterol 
0.165* 0.022 191 
Length of hospital 0.093 0.167 221 
Duration of follow up -0.163* 0.015 221 
NIHSS: National Institute of Health Stroke Scale, mRS: Modified Rankins Scale, 
R: Correlation coefficient 
 
 
Table 3: Comparison of serum uric acid levels with CVRFs in stroke patients 
Variable Normal SUA High SUA Total aOR (95% CI) P value 
Age > 45 years 119 (82.1) 60 (78.9) 179 0.819 (0.409-1.643) 0.574 
Male gender 91 (62.8) 43 (56.6) 134 0.773 (0.440-1.360) 0.372 
Hypertension 138 (95.2) 76 (100.0) 214 Undefined 0.099* 
Diabetes Mellitus 29 (20.0) 24 (31.6) 53 1.846 (0.980-3.474) 0.055 
Smoking 22 (15.2) 14 (18.4) 36 1.263 (0.605-2.636) 0.534 
Alcohol abuse 49 (57.6) 36 (47.4) 85 1.763 (1.001-3.108) 0.049 
Dyslipidemia 88 (60.7) 59 (77.6) 147 2.248 (1.192-4.238) 0.011 
Obesity/Overweight 25 (17.2) 23 (30.3) 48 2.083 (1.085-3.998) 0.026 
Metabolic syndrome 22 (15.2) 21 (27.6) 43 2.137 (1.085-4.202) 0.026 
Diuretic use 26 (18.4) 17 (23.0) 43 1.319 (0.662-2.627) 0.430 
Coronary artery disease 6 (4.1) 1 (1.3) 7 0.309 (0.163-2.365) 0.426* 
Atrial fibrillation 4 (2.8) 3 (3.9) 7 2.851 (0.541-15.014) 0.694* 
Heart disease 9 (6.2) 3 (3.9) 12 1.586 (0.488-4.342) 0.552* 
Valvulopathy 4 (2.8) 1 (1.3) 5 0.470 (0.052-4.281) 0.662* 
Previous stroke 20 (13.8) 11 (14.5) 31 1.058 (0.478-2.341) 0.890 
Chronic Kidney Disease 1 (0.7) 5 (6.6) 6 10.141 (1.163-88.445) 0.019* 
aOR: unadjusted odds ratio, CI: confidence interval 
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Table 4: Independent predictors of death within 3 months post stroke 
Variable 








AGE > 45 years 82 (78.8) 77 (83.7) 1.377 (0.666-2.847) 0.387 -- -- 
Male gender 67(64.4) 52(56.4) 0.718(0.404-1.276) 0.258 -- -- 
Unemployed 62(59.6) 44(47.8) 0.621(0.353-1.094) 0.098 0.788 (0.271-2.294) 0.662 
Unmarried 17(16.3) 17(18.5) 1.160(0.554-2.431) 0.694     
Insurance 33(31.7) 16(17.4) 0.453(0.230-0.893) 0.021 0.804 (0.245-2.638) 0.719 
Hypertension 103(99.0) 88(95.7) 0.214(0.023-1.947) 0.189 0.063 (0.005-0.863) 0.038 
Diabetes Mellitus 21(20.2) 28(30.4) 1.729(0.900-3.322) 0.098 1.114 (0.333-3.724) 0.861 
Smoking 24(23.1) 9(9.8) 0.361(0.158-0.825) 0.013 1.817 (0.465-7.092) 0.390 
Alcohol abuse 53(51.0) 27(29.3) 0.400(0.221-0.772) 0.002 0.414 (0.141-1.220) 0.110 
Dyslipidemia 79(76.0) 50(54.3) 0.377(0.205-0.693) 0.001 0.402 (0.126-1.284) 0.124 
OBESITY 30(28.8) 12(13.0) 0.377(0.205-0.693) 0.822 -- -- 
Metabolic syndrome 28(26.9) 9(9.8) 0.294(0.131-0.664) 0.002 0.702 (0.032-15.632) 0.823 
CAD/IHD 4(3.8) 2(2.2) 0.556(0.099-3.106) 0.686 -- -- 
Atrial fibrillation 2(1.9) 4(4.3) 2.318(0.415-12.962) 0.422 -- -- 
Heart disease 6(5.8) 5(5.4) 0.939(0.277-3.184) 0.919 -- -- 
Valvulopathy 3(2.9) 0(0.0) Undefined 0.249 -- -- 
Recurrent stroke 16(15.4) 10(10.9) 0.671(0.288-1.562) 0.352 -- -- 
CKD 1(1.0) 5(5..4) 5.920(0.679-51.636) 0.101 2.377 (0.150-37.742) 0.539 
GCS<9 6(5.8) 56(60.9) 25.407(10.080-64.045) <0.001 6.930 (2.199-21.836) 0.001 
Hyperurcemia 30(28.8) 35(38.0) 1.515(0.833-2.753) 0.172 1.072 (0.376-3.056) 0.897 
Complications 37(35.6) 57(62.0) 2.949(1.648-5.276) <0.001 1.792 (0.713-4.502) 0.214 
NIHSS>14 31(229.8) 80(87.0) 15.699(7.505-32.840) <0.001 4.166 (1.432-12.121) 0.009 
mRS>2 69(66.3) 90(97.8) 22.826(5.306-98..198) <0.001 5.351 (0.789-36.274) 0.086 
Hyperglycemia 24(23.1) 41(44.6) 2.680(1.450-4.952) 0.001 4.178 (1.356-12.872) 0.013 
Elevated Urea 17(16.3) 33(35.9) 2.862(1.462-5.605) 0.002 1.237 (0.322-4.752) 0.757 
Elevated Creatinine 26(25.0) 34(37.0) 1.759(0.952-3.248) 0.070 1.412 (0.351-5.681) 0.627 
High LDLc 76(73.1) 71(77.2) 1.246(0.649-2….390) 0.509 -- -- 
High TC 46(44.2) 56(60.9 1.961(1.109-3.469) 0.020 1.206 (0.420-3.461) 0.728 
High TG 14(13.5) 38(41.3) 4.524(2.248-9.105) <0.001 2.184 (0.705-6.765) 0.176 
Decreased HDLc 61(58.7) 32(34.8) 0.376(0.211-0.672) 0.001 0.559 (0.210-1.487) 0.244 
CAD/IHD; coronary artery/ischemic heart disease, CKD; chronic kidney disease, GCS; Glasgow coma score, NIHSS: National Institute of Health Stroke 
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Table 5: Independent predictors of poor outcome within 3 months post stroke 
Variable 
Functional Outcome Univariate analysis Multivariate analysis 
Good Poor 
Unadjusted  OR 
(95% CI) 
P Value 
Adjusted  OR 
(95% CI) 
P Value 
AGE > 45 years 48(76.2) 34(82.9) 1.518(0.559-4.122) 0.411 -- -- 
Male gender 44(69.8) 23(56.1) 0.552(0.243-1.251) 0.153 0.799 (0.228-2.798) 0.726 
Unemployed 40(63.5) 22(53.7) 0.666(0.299-1.482) 0.318 -- -- 
Unmarried 11(17.5) 6(14.6) 0.810(0.274-2.394) 0.703 -- -- 
Insurance 23(36.5) 10(24.4) 0.561(0.233-1.350) 0.194 0.858 (0.244-3.016) 0.811 
Hypertension 62(98.4) 41(100.0) Undefined 1.000 -- -- 
Diabetes Mellitus 13(20.6) 8(19.5) 0.932(0.348-2.495) 0.889 -- -- 
Smoking 15(23.8) 9(22.0) 0.900(0.352-2.303) 0.826 -- -- 
Alcohol abuse 36(57.1) 17(41.5) 0.531(0.239-1.179) 0.118 0.555 (0.195-1.583) 0.271 
Dyslipidemia 46(73.0) 33(80.5) 1.525(0.589-3.950) 0.384 -- -- 
OBESITY 18(28.6) 12(29.3) 1.035(0.435-2.461) 0.939 -- -- 
Metabolic syndrome 17(27.0) 11(26.8) 0.992(0.409-2.409) 0.986 -- -- 
CAD 4(6.3) 0(0.0) Undefined 0.152 -- -- 
Atrial fibrillation 2(3.2) 0(0.0) Undefined 0.518 -- -- 
Heart disease 6(9.5) 0(0.0) Undefined 0.042 -- -- 
Valvulopathy 3(4.8) 0(0.0) Undefined 0.277 -- -- 
Recurrent stroke 8(12.7) 8(19.5) 1.667(0.571-4.863) 0.347 -- -- 
CKD 1(1.6) 0(0.0) Undefined 1.000* -- -- 
GCS<9 1(1.6) 5(12.2) 8.611(0.968-76.635) 0.034* 2.486 (0.208-29.705) 0.472 
Hyperuricemia 15(23.8) 15(36.6) 1.846(0.781-4.364) 0.187 2.487 (0.711-8.699) 0.154 
Complications 18(28.6) 19(46.3) 2.159(0.949-4.912) 0.064 1.823 (0.559-5.940) 0.319 
NIHSS>14 12(19.0) 19(46.3) 3.671(1.524-8.838) 0.003 1.079 (0.348-3.348) 0.895 
mRS>2 29(46.0) 40(97.0) 46.897(6.056-362.566) <0.001 36.713 (4.280-314.931) 0.001 
Hyperlycemia 15(23.8) 9(22.0) 1.934(0.678-5.511) 0.212 -- -- 
Elevated urea 8(12.7) 9(22.0) 1.934(0.678-5.511) 0.212 -- -- 
Elevated creatinine 19(30.2) 7(17.1) 0.478(0.180-1.265) 0.132 0.289 (0.068-1.233) 0.094 
High LDLc 42(66.7) 34(82.9) 2.429(0.923-6.391) 0.068 1.028 (0.232-4.551) 0.971 
High TC 24(38.1) 22(53.7) 1.882(0.848-4.175) 0.118 2.323 (0.642-8.402) 0.199 
High TG 7(11.1) 7(17.1) 1.647(0.532-5.104) 0.384 -- -- 
Decreased HDLc 39(61.9) 22(53.7) 0.713(0.321-1.581) 0.404 -- -- 
CAD/IHD; coronary artery/ischemic heart disease, CKD; chronic kidney disease, GCS; Glasgow coma score, NIHSS: National Institute of Health 
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Figure 2: Graph showing a Kaplan-Meier survival rate of patients with normouricemia compared with 




Figure 3: Shows the death rate during admission across SUA quintiles 
 
